Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model

Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction

(2020) Peter Sinnaeve et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes

(2019) Robert F Storey et al.   EUROPEAN HEART JOURNAL

Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes

(2016) Anna Björquist et al.   THROMBOSIS AND HAEMOSTASIS

4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

(2015) Eva Caroff et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

(2015) C. Corinaldesi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Involvement of neutrophils in thrombus formation in living mice

(2014) R. Darbousset et al.   PATHOLOGIE BIOLOGIE

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

(2013) Ann Wittfeldt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome

(2013) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Regulation of Neutrophil Function by Adenosine

(2012) Kathryn E. Barletta et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation

(2012) R. Darbousset et al.   BLOOD

Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

(2011) J. J. J. van Giezen et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Thienopyridines, but Not Elinogrel, Result in Off-Target Effects at the Vessel Wall That Contribute to Bleeding

(2011) P. Andre et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Regulating thrombus growth and stability to achieve an optimal response to injury

(2011) L. F. BRASS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Historical perspective and future directions in platelet research

(2011) B. S. COLLER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

P2Y1 and P2Y13 purinergic receptors mediate Ca2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells

(2010) Taras Lyubchenko et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Laser-induced endothelial cell activation supports fibrin formation

(2010) B. T. Atkinson et al.   BLOOD

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects

(2010) Renli Teng et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases

(2010) Steffen Massberg et al.   NATURE MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombus stability on the vessel wall

(2008) A. T. Nurden   BLOOD